Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure

NCT00025727 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

330

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Lopinavir/Ritonavir
DRUG: Ritonavir
DRUG: GW433908

Sponsor

GlaxoSmithKline